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Teratogen city of Di(2-ethylhexyl) Phthalate
(DEHP) and Di-n-butyl Phthalate (DBP)
in Mice
by Kohei Shiota* and Hideo Nishimura*t
Di(2-ethylhexyl) phthalate (DEHP) and di-n-butyl phthalate (DBP) were mixed with diet at
graded levels of 0.05, 0.1, 0.2, 0.4 and 1.0 wt-% and given to pregnant ICR mice throughout
gestation. Maternal weight gain was suppressed and fetal resorptions increased at 0.2, 0.4 and
1.0%o levels ofDEHP and 1.0%o level ofDBP. All the implanted ova died early in rats fed 0.4 and
1.0% levels of DEHP. External malformations increased significantly by 0.2% DEHP, and 1.0%
DBP showed borderline significance. The major malformations in treated groups were neural
tube defects (exencephaly and myeloschisis), suggesting that the phthalic acid esters (PAEs)
affect neural tube closure in developing embryos. Treatment with the compounds caused
intrauterine growth retardation and delayed ossification with an apparently dose-related
response pattern. These results indicate that a high dose of DEHP and DBP might be
embryotoxic andteratogenic in mice. The maximumnonembryotoxic doses ofPAEs in mice were
more than 2000 times the estimated level of human intake through the food chain. Thus it is
assumed that the current "normal" exposure level ofPAEs does not pose an imminent threat to
human fetal development.
Introduction
Phthalic acid esters (PAEs) have been reported
to leach into plasma from blood storage bags (1) and
hemodialysis units (2). These compounds have also
been found in a variety of materials in the en-
vironment, including foodstuffs (3). Thus, pregnant
women might be at risk for unintentional exposure
to minute amounts of PAEs derived from medical
devices and diet.
In recent years, many studies have been carried
out onthepossiblehealthhazardsofPAEs, including
the effects on reproduction and fetal development,
andthey havebeenextensivelyreviewed byseveral
investigators (4-6). However, there is still apaucity
or inconsistency of teratological information of
PAEs. Singh et al. (7) injected several kinds of
PAEs intraperitoneally into rats on days 5, 10 and
15 of gestation. Fetal resorptions and gross ab-
normalities increased on injection of 10 ml/kg di(2-
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ethylhexyl) phthalate (DEHP) and 1.02 ml/kg di-n-
butyl phthalate (DBP). Skeletal abnormalities and
hematomas were observed at 0.610 and 0.305 ml/kg
levels of DBP. Nikonorow et al. (8) administered
0.34 and 1.70 g/kg/day DEHP and 0.12 and 0.60
g/kg/day DBP orally to rats during pregnancy and
observed increased resorptions and decreased fetal
weight, but no gross malformations. In a mouse
study, consecutive oral administration of10mg/day
DEHP and 10 and 50 mg/day DBP to pregnant
females ofICR andddYstrainsinducedabnormalities
in their offspring, includingrenal cysts and absence
of tail (9). In this short report, however, the data
werenotcomparedwithappropriate controls. Single
oral administration ofDEHP to pregnant mice ofa
random strain on day 7 of gestation resulted in
decreased fetal weight at a dose level of0.05 ml/kg
and increased number of dead and malformed
fetuses at 0.1 ml/kg (10). Teratogenicity in chicks
has beenreported by Haberman and his co-workers
(11-13). Mutagenicand antifertility effectsofDEHP
have been shown by Singh et al. (14) by dominant
lethal test in mice.
The present study was undertaken to ascertain
the effects of orally administered DEHP and DBP66
on embryonic development and to determine the
maximum nonembryotoxic dose in mice for extra-
polation to the human. In the present experiment,
the test compounds were given to the animals with
dietthroughout thewhole gestation period, because
they are ingested by people mainly through the
food chain.
Materials and Methods
DEHP and DBP manufactured by Tokyo Kasei
Industrial Co., Ltd. (Tokyo) were provided by the
Ministry of Health and Welfare, Japan. They were
individuallymixedwiththebasaldiet) OA-2(CLEA
Japan, Inc., Takatsuki) at graded levels of 0.05,
0.1, 0.2, 0.4 and 1.0 wt-%; the highest dose level
was estimated to be near the maximum nontoxic
dose for mature female ICR mice by a preparatory
subehronic study for 3 weeks.
Four-week-old male and female mice ofICR-JCL
strain were purchased from CLEAJapan, Inc. and
reared in our laboratory with laboratory chow
(OA-2) and tap water ad libitum. The room
temperature was kept at 22 + 2°C and the relative
humidity at 55 + 5%. The dailylight cycle was 12 hr
light and 12 hr dark. Each female mouse at 8-16
weeks of age was placed overnight with a male of
proven fertility. The day on which a vaginal plug
was found was taken as day zero of pregnancy. The
femaleswithvaginalplugs wererandomlydistributed
into ten test groups and one control group. The
femalesinthetest groups werefedpelletscontaining
DEHP or DBP at the graded levels mentioned
above from day zero until the day of sacrifice. The
control animals were fed the basal diet only. During
the gestation period, the females were weighed
daily, and food and water consumptions recorded
daily.
On day 18 of pregnancy, the females were
sacrificed by cervical dislocation. The uteri were
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removed, and implantations, resorptions and dead
fetuses wererecorded. The livefetuses wereweighed,
sexedandinspected for grossexternalabnormalities.
About halfofthe fetuses from eachlitter, randomly
selected, were eviscerated, fixed in 95% ethanol,
cleared in 1% KOH, and stained with alizarin red S
fordetectionofskeletalabnormalities. Theremaining
fetuses were fixed in Bouin solution for several
daysandexaminedforinternalsofttissueanomalies
by microdissection under a dissecting microscope.
The data concerning maternal weight and food
and water consumption were analyzed by Student's
t test for comparing means between groups. The
datarelatingfetuses were analyzed in the following
way in order to minimize biases resulting from the
litter effect (15). The percentages or means for a
group were computed by first obtaining the per-
centage or mean for each litter and then calculating
the average of these percentages or means. The
distribution of a percentage or a mean for treated
litters was compared with the control distribution
by use ofthe Wilcoxon rank sum test (16).
Results
Maternal Food, Water and PAE
Intake
The average food intake by the treated females
ranged from 6.1 to 7.4 g/day, and these did not
differ significantly from the amount taken by the
control mice (Table 1). No dose-related trends were
noted in food consumption. The average daily doses
of DEHP calculated from food intake and body
weight were 2200, 830, 410, 190 and 70 mg/kg for
doselevelsof1.0, 0.4,0.2, 0.1and0.05%, respectively.
The corresponding doses of DBP were 2100, 660,
370, 180 and 80 mg/kg for the respective dose
levels. The daily water intake was not significantly
different in treated and control groups.
Table 1. Effects of DEHP and DBP on pregnant mice.
Phthalate Number Average food PAE dosage, Averagematernalweight, g(mean ± SE)
Phthalate dose, % of dams intake, g/day mg/kg/day Day 0 Day 18
DEHP 1.0 12 7.2 2,200 30.2 ± 0.4 37.4 ± 1.2a
DEHP 0.4 7 7.2 830 31.4 ± 0.9 38.1 ± 1.la
DEHP 0.2 24 6.9 410 29.0 ± 0.8 42.6 ± 2.2b
DEHP 0.1 9 7.4 190 29.2 ± 0.6 49.9 ± 1.3
DEHP 0.05 8 6.1 70 31.6 ± 0.8 56.6 ± 1.1
DBP 1.0 15 7.1 2,100 30.4 + 0.4 39.7 ± 1.6a
DBP 0.4 9 6.9 660 29.9 ± 0.3 53.5 ± 2.9
DBP 0.2 21 7.1 370 30.1 ± 0.7 52.6 ± 2.5
DBP 0.1 8 7.3 180 29.5 ± 0.4 52.2 ± 1.8
DBP 0.05 7 6.9 80 29.3 ± 0.3 56.3 ± 1.5
Control 8 6.2 - 29.2 ± 0.4 52.6 ± 1.1
aSignificantly different from control mice (p < 0.01).
bSignificantly different from control mice (0.01 < p < 0.05).TERATOGENICITY OF PHTHALATE ESTERS
Effects on Dams
No mortality or behavioral abnormalities were
observed in the pregnant mice throughout the
experimental period. However, thematernalweight
was significantly depressed duringthelatergestation
period in the groups given 1.0, 0.4 and 0.2% DEHP
and 1.0% DBP (Table 1). Such weight suppression
ofthemothers couldbe accounted forbytheincreased
early resorptions in these groups. At autopsy, no
gross pathological changes were noted in maternal
major organs.
Effects on Fetal Viability and Weight
There was no significant difference in the mean
numbers ofcorporalutea and implantations between
the treated and control groups (Table 2). Fetal
mortality increased in a dose-related manner, and it
was significantly higher in 1.0, 0.4 and 0.2% DEHP
and 1.0% DBP groups. No viable term fetuses were
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obtained at the two highest doses of DEHP. Most
of the fetal deaths were very early resorptions.
The average weight of viable fetuses showed a
dose-related decrease in the treated groups, and
that in 0.2% DEHP group and 0.4% DBP group
(male only) was significantly lower than in controls
(Table 2). Out of the 15 pregnant females which
were given 1.0% DBP, only three fetuses from two
dams survived to term. Their weights were far
lower than those of controls.
External Anomalies
Several kinds ofmalformations were observed in
the treated groups (Table 3). The incidence of
malformed fetuses in 0.2% DEHP group was signi-
ficantly higher than in the control group (p < 0.05).
Thedifferencebetween 1.0% DBPandcontrol groups
was at the borderline level of significance (p
0.05). The most common malformations were neural
tube defects (exencephaly and myeloschisis), and
Table 2. Effects of DEHP and DBP on fetal viability and development.
Phthalate Number Number of implants Resorptions and Fetal weight, g (mean ± SE)
Phthalate dose, % of litters (means ± SE) dead fetuses, % Male Female
DEHP 1.0 12 12.6 ± 0.5 100.0a -
DEHP 0.4 7 15.0 ± 1.2 100.0a
DEHP 0.2 24 11.1 ± 0.9 67.8a 1.12 ± 0.07a 1.16 ± 0.04
DEHP 0.1 9 12.6 ± 2.1 31.0c 1.28 ± 0.08 1.21 ± 0.07
DEHP 0.05 8 13.3 ± 1.7 7.5 1.32 ± 0.07 1.29 ± 0.06
DBP 1.0 15 12.1 ± 0.5 98.4a 1.03, 1.24 0.80
DBP 0.4 9 12.0 ± 0.8 11.4 1.10 ± 0.18b 1.06 ± 0.20
DBP 0.2 21 12.4 ± 0.8 22.3 1.31 ± 0.07 1.24 ± 0.06
DBP 0.1 8 12.0 ± 2.9 11.2 1.29 ± 0.10 1.22 ± 0.08
DBP 0.05 7 12.7 ± 3.1 3.7 1.31 ± 0.04 1.29 ± 0.03
Control 8 10.8 ± 1.9 5.0 1.41 ± 0.07 1.35 ± 0.07
aSignificantly different from control mice (p < 0.01).
bSignificantly different from control mice (0.01 < p < 0.05).
cDifference from controls is at the borderline level of significance (p 0.05).
Table 3. Malformations in mouse fetuses from dams treated with DEHP or DBP.
Phthalate Number (%) of
Phthalate dose, % malformed fetuses Type of malformation and (no. ofcases)c
DEHP 1.0
DEHP 0.4
DEHP 0.2 14 (25.8)a Ex (3), Ex+OE (2), Ex+TA (1), My (1), My+GS+CF (1),
My+OE+GE (1), GS+TA (1), TA (4)
DEHP 0.1 3 (5.3) Ex (2), OE (1)
DEHP 0.05 0 (0.0)
DBP 1.0 2 (75.0)b Ex (2)
DBP 0.4 0 (0.0)
DBP 0.2 1 (0.5) OE (1)
DBP 0.1 0 (0.0)
DBP 0.05 0 (0.0)
Control 0 (0.0)
aSignificantly different from control mice (p < 0.05).
bDifference from controls is at the borderline level of significance (p 0.05).
'Type of malformation: CF club foots; Ex, exencephaly; GE, generalized edema; GS, gastroschisis; My, myeloschisis; OE, open
eyelids; TA, tail anomaly.Table 4. Effects of DEHP and DBP on skeletal development of mouse fetuses.
Number Variations ( Number of
Phthalate of fetuses Skeletal Deficient ossification ossified coccygia
Phthalate dose, % examined malformations Lumbar rib of sternebrae (mean ± SE)
DEHP 1.0 0
DEHP 0.4 0 - - -
DEHP 0.2 40 0 18.7 8.3 6.5 ± 0.6a
DEHP 0.1 35 0 20.7 14.7 9.2 ± 0.3
DEHP 0.05 31 0 7.6 0.0 7.3 ± 0.4a
DBP 1.0 0 0 - -
DBP 0.4 42 0 36.9 0.0 2.6 ± 0.4a
DBP 0.2 65 0 26.3 0.0 6.0 + 0.4a
DBP 0.1 38 0 17.2 0.0 4.5 ± 0.3a
DBP 0.05 41 0 23.8 6.3 5.1 ± 0.3a
Control 0 0 13.3 0.0 9.4 + 0.2
aSignificantly different from control mice (p < 0.05).
Table 5. Reported teratogenicity/embryotoxicity of DEHP in rodents.
Species Route of Period of
(strain) administration administration Dose Principal findings Authors
Mouse PO Throughout 190-2200 Neural tube defects, tail anomalies, Present study
(ICR) gestation mg/kg/day decreased fetal weight, delayed
ossification, resorptions
Mouse PO Throughout 10 mg/day Renal cysts Onda et al. (9)
(ICR, ddY) gestation
Mouse PO Day 7 0.05 ml/kg Decreased fetal weight Nakamura et al. (10)
(ddY-Slc x CBA) 0.1 ml/kg Fetal deaths, skeletal abnormalities
Rat PO Throughout 0.34, 1.70 Resorptions, decreased fetal weight, Nikonorow et al. (8)
(Wistar) gestation g/kg/day decreased placental weight
Rat PO Days 3, 6, 9 2.4 Decreased implantations Peters and Cook (31)
(Sprague-Dawley) ml/kg/day
Rat IP Days 5, 10, 10 ml/kg/dayMalformations, resorptions, Singh et al. (7)
(Sprague-Dawley) 15 decreased fetal weight
these anomalies were occasionally encountered also
in dead fetuses. Other anomalies consisted of gas-
troschisis, absence or shortness of tail, club foot,
open eyelids and generalized edema.
Skeletal and Visceral Anomalies
As shown in Table 4, extra lumbar ribs and
deficientossificationofsternebraeincreasedintreated
groups, although the difference from the controls
was not statistically significant. Ossification was
significantlyretarded intreated groupsexcept 0.1%
DEHP group. Delayed ossification in those groups
was probably related to the general underdevel-
opment ofthe fetuses. No internal anomalies were
observed by microdissection.
Discussion
The results of the present experiment indicate
that DEHP and DBP can affect fetal development
when they are taken orally during pregnancy.
Although there appears to be no adverse effect on
implantation, a dose-related response was observed
for fetal mortality and fetal body weight. It was
also shown that DEHP and DBP provoke their
teratogenicity in mice at high dosages.
Inthetwopreviousexperiments, inwhich DEHP
and/or DBP was given orally to pregnant mice (9,
10), cysts of the kidney, absence of tail (9) and
skeletal abnormalities (10) werenoted, butnoneural
tube defects were observed. On the contrary, renal
cysts were not found inthe present studybycareful
visceral examination. It is also interesting to note
that a certain difference inembryotoxicity has been
shown between mice and rats, and between oral
(PO) and parenteral (IP) administration (Tables 5
and 6). At present, there is no clear explanation for
such inconsistency between experiments. Although
recentmetabolic studies have shownthatPAEs are
metabolized in rats after oral administration (17-19)
and IV injection (20), comparative data are still
insufficientinthemouseandhuman. Itseemspossible
thatthemetabolismofPAEsisnotthesamebetween
species and between strains. Thus comparative
aspects of PAE metabolism and potential embry-
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Table 6. Reported teratogenicity/embryotoxicity of DBP in rodents.
Species Route of Period of
(strain) administration administration Dose Principal findings Authors
Mouse PO Throughout 660, 2100 Neural tube defects, resorptions, Present study
(ICR) gestation mg/kg/day decreased fetal weight,
delayed ossification
Mouse PO Throughout 10, 50 Renal cysts, absence of tail Onda et al. (9)
(ICR, ddY) gestation mg/day
Rat PO Throughout 0.12, 0.60 Resorptions, decreased fetal weight Nikonorow et al. (8)
(Wistar) gestation g/kg/day
Rat IP Days 5, 10, 0.61, 0.305 Decreased fetal weight, skeletal Singh et al. (7)
(Sprague-Dawley) 15 ml/kg/day abnormalities
1.02 Decreased fetal weight, resorptions
ml/kg/day
otoxicity of the metabolites should be ascertained.
Pertinent animal models in terms of the pharma-
cokinetic similarity to humans are needed.
From the findings of our experiment, it seems
reasonable to assume that the maximumnonembry-
otoxic doses of orally administered PAEs in mice
would be at least 70 mg/kg/day for DEHP and 370
mg/kg/day for DBP. On the other hand, the current
human intake of PAEs from the diet has been
estimated to be 0.03 mg/kg/day at maximum in the
case of the Japanese (10, 21). Thus the maximum
nonembryotoxic doses in mice are more than 2000
times the current humanexposure levelreported so
far. Forthisreason, it seemsunlikelythatingestion
of PAEs under the current environmental level
would pose an imminent threat to human early
development. The following facts also favor this
assumption. First, pharmacokinetic studies show
that DEHPismetabolized and eliminated rapidlyin
mice (22, 23), rats (18, 24) and humans (1, 25).
Second, Singh et al. (26) found that in rats the
levels ofphthalate diesters in a whole fetus did not
exceed the level in the maternal blood. In the
human, DEHP and DBP in cord blood were at
about the same levels as in the maternal blood (27).
Thus, no fetal accumulation of PAEs is likely to
occur. Third, Garvin et al. (28) and Lewandowski et
al. (29) injected IV the plasma-soluble extracts of
poly(vinyl chloride) (PVC) to pregnant rats and
found no evidence of teratogenic or embryotoxic
effects. In one ofthe experiments (29), the highest
dose ofthe extract was equivalent to 5.3 mgDEHP/
kg/day, which is similar to the amount predicted to
bereceivedbya60-kghumanundergoinganexchange
transfusion of 21-day-old blood.
Although placental transfer of PAEs has been
studied inrats (26), thereisnoinformationconcerning
the accumulation of PAEs in human conceptuses.
Since there is little expectation of human in vivo
study, actual determination of the PAE levels in
human embryonic and fetal tissues and comparison
of those with the levels in experimental animals
with recognizable embryotoxicity would enable us
to assess how safe the current environmental level
is to human conceptuses. Such determination of
fetal tissue levels could be done by utilizing the
tissues from induced human abortuses (30).
From the discussion above, it can be concluded
that the current "normal" dietary exposure level of
PAEs may be harmless to human development.
However, the problem ofhigh level exposure in the
human has not yet been solved. Epidemiological
studies are needed regarding the reproductive
outcome in populations underhigh level exposure of
PAEs, e.g., among woman workers in the PVC and
car industries.
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